Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $68.72 USD
Change Today +2.11 / 3.17%
Volume 119.8K
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

biospecifics technologies (BSTC) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/28/15 - $71.59
52 Week Low
08/4/14 - $26.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

biospecifics technologies (BSTC) Related Bloomberg News

View More Bloomberg News

biospecifics technologies (BSTC) Related Businessweek News

No Related Businessweek News Found

biospecifics technologies (BSTC) Details

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX brand in Canada, Australia, Brazil, and Mexico, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, human lipoma, canine lipoma, and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

5 Employees
Last Reported Date: 03/16/15
Founded in 1957

biospecifics technologies (BSTC) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2014.

biospecifics technologies (BSTC) Key Developments

BioSpecifics Technologies Corp. Announces Asahi Kasei Pharma Corporation Receives Approval of XIAFLEX in Japan for the Treatment of Dupuytren's Contracture

BioSpecifics Technologies Corp. announced that Asahi Kasei Pharma Corporation (Asahi Kasei) has received approval for its regulatory application to the Japanese Pharmaceutical and Medical Device Agency (PMDA) for XIAFLEX (collagenase clostridium histolyticum) for the treatment of patients with Dupuytren's contracture in Japan. Asahi has the rights to develop and market XIAFLEX in Japan through an agreement with BioSpecifics' partner Endo International plc (Endo). BioSpecifics will receive a milestone payment upon commercial launch in Japan.

BioSpecifics Technologies Corp. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 03:00 PM

BioSpecifics Technologies Corp. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 03:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Thomas L. Wegman, Chief Executive Officer, President, Principal Financial Officer, Principal Accounting Officer, Secretary, Director, President of ABC-Curacao, President of ABC-New York, Secretary of ABC-Curacao, Secretary of ABC-New York, Director - ABC-Curacao and Director of ABC-New York.

BioSpecifics Technologies Corp. Announces Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015

BioSpecifics Technologies Corp. announced consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $5,606,454 compared with $2,757,601 for the same period a year ago. Operating income was $3,563,867 compared with $1,128,592 for the same period a year ago. Income before income tax expense was $3,582,220 compared with $1,140,391 for the same period a year ago. Net income was $2,330,900 or $0.32 per diluted share compared with $753,989 or $0.11 per diluted share for the same period a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSTC:US $68.72 USD +2.11

BSTC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BSTC.
View Industry Companies

Industry Analysis


Industry Average

Valuation BSTC Industry Range
Price/Earnings 78.7x
Price/Sales 27.4x
Price/Book 13.8x
Price/Cash Flow 74.4x
TEV/Sales 26.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSPECIFICS TECHNOLOGIES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at